Impact of lipoxin-mediated regulation on immune response to infectious disease

Immunologic Research

Volumn 35, Issue 3, 2006, Pages 209-218

  Machado, Fabiana S ^a   Aliberti, Julio ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Dendritic cells; Interleukin 12; Lipoxin; SOCS 2; Toxoplasma gondii

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; GAMMA INTERFERON; INTERLEUKIN 12; LIPOXIN; LIPOXYGENASE; TUMOR NECROSIS FACTOR;

CELLULAR IMMUNITY; CHRONIC DISEASE; CYTOKINE PRODUCTION; DISEASE CONTROL; HOST PARASITE INTERACTION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOREGULATION; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ANIMALS; CYTOKINES; HOST-PARASITE RELATIONS; HUMANS; INFECTION; LIPOXINS; SIGNAL TRANSDUCTION; TOXOPLASMOSIS;

EID: 33845864448     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:35:3:209     Document Type: Review

References (53)

1. Martinez AJ, et al: The neuropathology and epidemiology of AIDS. A Berling experience. A review of 200 cases. Pathol Res Pract 1995;191:427-443.
2. Morisaki JH, Heuser JE, Sibley LD: Invasion of Toxoplasma gondii occurs by active penetration of the host cell. J Cell Sci 1995;108(Pt 6):2457-2464.
3. Black MW, Boothroyd JC: Lytic cycle of Toxoplasma gondii. Microbiol Mol Biol Rev 2000;64:607-623.
4. Hay J, Hutchison WM: Toxoplasma gondii - an envoronmental contaminant. Ecol Dis 1983;2:33-43.
5. Scharton-Kersten TM, et al: In the absence of endogenous IFN-gamma, mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection. J Immunol 1996;157:4045-4054.
6. Dickens M, et al: A cytoplasmic inhibitor of the JNK signial transduction pathway. Scinece 1997;277:693-696.
7. Liu C, Fan Y, Dias A, et al: Cutting edge: dendritic cells are essential for in vivo interleukin-12 production and development of resistance againt Toxoplasma gondii infecttion in mice. J Immunol 2006;177:31-35.
8. Reis e Sousa C, et al: In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas. J Exp Med 1997;186:1819-1829.
9. Scanga CA, et al: Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. J Immunol 2002;168:5997-6001.
10. Yarovinsky F, et al: TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 2005;308:1626-1629.
11. Aliberti J, et al: CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha+ dendritic cells. Nat Immunol 2000;1:83-87.
12. Aliberti J, et al: Molecular mimicry of a CCR5 binding-domain in the microbial activation of dendritic cells. Nat Immunol 2003;4:485-490.
13. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-146.
14. Mason NJ, et al: TRA F6-dependent mitogen-activated protein kinase activation differentially regulates the production of interleukin-12 by macrophages in response to Toxoplasma gondii. Infect Immun 2004;72:5662-5667.
15. Scharton-Kersten T, Contursi C, Masumi A, Sher A, Ozato K: Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction. J Exp Med 1997;186:1523-1534.
16. Tsujimura H, et al: ICSBP/IRF-8 retrovirus transduction rescues dendritic cell development in vitro. Blood 2003;101:961-969.
17. Hunter CA, Chizzonite R, Remington JS: IL-1 beta is required for IL-12 to induce production of IFN-gamma by NK cells. A role for IL-1 beta in the T cell-independent mechanism of resistance against intracellular pathogens. J Immunol 1995;155:4347-4354.
18. Sher A, Oswald IP, Hieny S, Gazzinelli RT: Toxoplasma gondii induces a T-independent IFN-gamma response in natural killer cells that requires both adherent accessory cells and tumor necrosis factor-alpha. J Immunol 1993;150:3982-3989.
19. Yap GS, Sher A: Cell-mediated immunity to Toxoplasma gondii: initiation, regulation and effector function. Immunobiology 1999;201:240-247.
20. Karp CL, Wills-Karp M: Complement and IL-12: yin and yang. Microbes Infect 2001;3:109-119.
21. Son ES, Song KJ, Shin JC, Nam HW: Molecular clonning and characterization of peroxiredoxin from Toxoplasma gondii. Korean J Parasitol 2001;39:133-141.
22. van de Loo FA, van den Berg WB: Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators. Rheum Dis Clin North Am 2002;28:127-149.
23. Wille U,Villegas EN, Striepen B, Roos DS, Hunter CA: Interleukin-10 does not contribute to the pathogenesis of a virulent strain of Toxoplasma gondii. Parasite Immunol 2001;23:291-296.
24. Deckert-Schluter M, et al: Interleukin-10 downregulates the intracerebral immune response in chronic Toxoplasma encephalitis. J Neuroimmunol 1997;76:167-176.
25. Gazzinelli RT, et al: In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J Immunol 1996;157:798-805.
26. Suzuki Y, et al: IL-10 is required for prevention of necrosis in the small intestine and mortality in both genetically resistant BALB/c and susceptible C57BL/6 mice following peroral infection with Toxoplasma gondii. J Immunol 2000;164:5375-5382.
27. Salek-Ardakani S, Arrand JR, Mackett M: Epstein-Barr virus encoded interleukin-10 inhibits HLA-class I, ICAM-1, and B7 expression on human monocytes: implications for immune evasion by EBV. Virology 2002;304:342-351.
28. Fiorentino DF, et al: IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cell. J Immunol 1991;146:3444-3451.
29. Nathan C: Points of control in inflammation. Nature 2002;420:846-852.
30. Reis e Sousa C, et al: Paralysis of dendritic cell IL-12 production by microbial products prevents infection-indued immunopathology, Immunity 1999;11:637-647.
31. Aliberti J, Serhan C, Sher A: Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J Exp Med 2002;196:1253-1262.
32. Goh J, Godson C, Brady HR, Macmathuna P: Lipoxins: pro-resolution lipid mediators in intestinal inflammation. Gastroenterology 2003;124:1043-1054.
33. Kieran NE, Maderna P, Godson C: Lipoxins: potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease. Kidney Int 2004;65:1145-1154.
34. Samuelsson B: Arachidonic acid metabolism: role in inflammation. Z Rheumatol 1991;50 Suppl 1:3-6.
35. Van Dyke TE, Serhan CN: Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J Dent Res 2003;82:82-90.
36. Bandeira-Melo C, et al: Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi LXA4 block allergen-induced eosinophil trafficking. J Immunol 2000;164:2267-2271.
37. Clish CB, et al: Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc Natl Acad Sci USA 1999;96:8247-8252.
38. Hachicha M, Pouliot M, Petasis NA, Serhan CN: Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J Exp Med 1999;189:1923-1930.
39. Ohira T, et al: A stable aspiri-triggered lipoxin A4 analog blocks phosphorylation of leukocyte-specific protein 1 in human neutrophils. J Immunol 2004;173:2091-2098.
40. Ramstedt U, Ng J, Wigzell H, Serhan CN, Samuelsson B: Action of novel eicosanoids lipoxin A and B on human natural killer cell cytotoxicity: effects on intracellular cAMP and target cell binding. J Immunol 1985;135:3434-3438.
41. Maddox JF, et al: Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J Biol Chem 1997;272:6972-6978.
42. Schaldach CM, Riby J, Bjeldanes LF: Lipoxin A4: a new class of ligand for the Ah receptor. Biochemistry 1999;38:7594-7600.
43. Devachand PR, et al: Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J 2003;17:652-659.
44. Machado FS, et al: Anti-inflammatory actions of lipoxin A(4) and aspirin triggered lipoxin are SOCS-2 dependent. Nat Med 2006;12:330-334.
45. Funk CD, Chen XS, Johnson EN, Zhao L: Lipoxygenase genes and their targeted distuption. Prostaglandins Other Lipid Mediat 2002;68-69:303-312.
46. Leonard MO, et al: 15-Epi-16-(para-flourophenoxy)-lipoxin A(4)-methyl ester, a synthetic analogue of 15-epilipoxin A(4), is protective in experimental ischemic acute renal failure. J Am Soc Nephrol 2002;13:1657-1662.
47. Alexander WS, Hilton DJ: The role of suppressors of cytokne signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 2004;22:503-529.
48. Kile BT, et al: The SOCS box: a tale of destruction and degradation. Trends Biochem Sci 2002;27:235-241.
49. Karp CL, et al: Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004;5:388-392.
50. Jung YJ, LaCourse R, Ryan L, North RJ: Evidence inconsistent with a negative influence of T helper 2 cells on protection afforded by a dominant T helper 1 response against Mycobacterium tuberculosis lung infection in mice. Infect Immun 2002;70:6436-6443.
51. Bafica A, et al: Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J Clin Invest 2005;115:1601-1606.
52. Bannenberg GL, Aliberti J, Hong S, Sher A, Serhan C: Exogenous pathogen and plant 15-lipoxygenase initiate endogenous lipoxin A4 biosynthesis. J Exp Med 2004;199:515-523.
53. Vance RE, Hong S, Gronert K, Serhan CN, Mekalanos JJ: The opportunistic pathogen Pseudomonas aeruginosa carries a secretable arachidonate 15-lipoxygenase. Proc Natl Acad Sci USA 2004;101:2135-2139.